You are here

Article Text

Article menu

This article has a correction. Please see:

Download PDFPDF
Recent advances in clinical practice
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma
  1. Alexander Gerbes1,
  2. Fabien Zoulim2,3,
  3. Herbert Tilg4,
  4. Jean-François Dufour5,6,
  5. Jordi Bruix7,
  6. Valérie Paradis8,
  7. Riad Salem9,
  8. Markus Peck-Radosavljevic10,
  9. Peter R Galle11,
  10. Tim F Greten12,13,
  11. Jean-Charles Nault14,15,16,
  12. Matias A Avila17
  1. 1 Department of Medicine 2, Liver Center Munich, University Hospital, LMU, Munich, Germany
  2. 2 Hepatology Department at the Hospices Civils de Lyon, Lyon University, Institut Universitaire de France, Lyon, France
  3. 3 Viral Hepatitis Team, Cancer Research Center of Lyon (CRCL), INSERM, Lyon University, Lyon, France
  4. 4 Department of Internal Medicine I, Gastroenterology, Hepatology & Endocrinology, Innsbruck Medical University, Innsbruck, Austria
  5. 5 Hepatology, Department of Clinical Research, University of Bern, Bern, Switzerland
  6. 6 University Clinic of Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland
  7. 7 BCLC Group, Liver Unit, Hospital Clínic, Universitat de Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain
  8. 8 Pathology Department Beaujon Hospital & INSERM, INSERM 1149, University Paris-Diderot, Paris, France
  9. 9 Department of Radiology, Section of Vascular and Interventional Radiology, Northwestern University, Chicago, Illinois, USA
  10. 10 Department of Gastroenterology & Hepatology, Endocrinology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
  11. 11 Department of Internal Medicine, University Medical Center I, Mainz, Germany
  12. 12 National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA
  13. 13 Gastrointestinal Malignancy Section, Thoracic and GI Oncology Branch, Center for Cancer Research, Bethesda, Maryland, USA
  14. 14 Unité Mixte de Recherche 1162, Génomique fonctionnelle des tumeurs solides, Institut National de la Santé et de la Recherche Médicale, Paris, France.
  15. 15 Liver unit, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Paris, France
  16. 16 Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris 13, Communauté d’Universités et Etablissements Sorbonne Paris Cité, Paris, France
  17. 17 Programme of Hepatology, CIMA, IdiSNA, CIBERehd, University of Navarra, Pamplona, Spain
  1. Correspondence to Professor Alexander Gerbes, Department of Medicine 2, University Hospital, LMU Munich, Marchioninistr. 15. D-81377 München, Munich, Germany; Gerbes{at}med.uni-muenchen.de and Professor Matias A Avila, Hepatology Programe, CIMA, IdiSNA, CIBERehd, University of Navarra, Avda, Pio XII, n55. Pamplona 31008, Spain; maavila{at}unav.es

Abstract

Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge. While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials. This manuscript targets therapeutic advances and most burning issues. Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy. Therapeutic topics highlighted are locoregional techniques, combination therapies and the potential of immunotherapy. Finally the manuscript provides a critical evaluation of novel targets and strategies for personalized treatment of HCC.

  • hepatocellular carcinoma
  • clinical trials

https://doi.org/10.1136/gutjnl-2017-315068

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors All authors were involved in drafting and reviewing the manuscript and had approval of the final version submitted.

    • Competing interests J-FD Advisory committees: Abbvie, Bayer, BMS, Falk, Genfit, Gilead Science, Intercept, Lilly, Merck, Novartis. Speaking and teaching: Abbvie, Bayer, BMS, Genfit, Gilead Science, Novartis. Unrestricted research grant: Bayer. JB Consultancy for Abbvie, Arqule, Bayer, BMS, Boehringer Ingelheim BTG, Eisai, Gilead, Kowa, Novartis, Onxeo, Roche, Sirtex and Terumo. Research contract with Bayer. MP-R Investigator: Abbott, Arqle-Daiichi, Bayer, BMS, Boehringer-Ingelheim, Gilead, Imclone, Novartis, Roche. Speaker, Advisor: Abbott, Bayer, BMS, Boehringer-Ingelheim, Gilead, MSD, Roche. Grant Support: Abbott, Bayer, Gilead, MSD, Roche. DSMB: Lilly-Imclone, ONXEO. RS Advisor to Bayer, BTG, Terumo, Merit, Cook. PRG Honoraria for lecturing and participation in advisory boards from Bayer, Lilly, Sirtex, Sillajen, BMS, MSD.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles